Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Cognition Therapeutics, Inc. (CGTX)
Company Research
Source: GlobeNewswire
- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting -- Actively Evaluating Strategy Across DLB and Alzheimer’s Disease - PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program for zervimesine in mild-to-moderate Alzheimer's disease during the annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Cognition discussed the program design with the U.S. Food and Drug Administration (FDA) during an end-of-Phase 2 meeting. The CTAD poster will be available on the Publications page of the company website in accordance with the conference embargo policy. The Phase 3 program is expected to enroll adults with mild-to-moderate Alzheimer's disease who have lower levels of plasma p-tau217 at screening. Based on Phase 2 clinical study results, the Company believes
Show less
Read more
Impact Snapshot
Event Time:
CGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGTX alerts
High impacting Cognition Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGTX
News
- Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
- Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesGlobeNewswire
- Cognition Therapeutics (NASDAQ:CGTX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold [Seeking Alpha]Seeking Alpha
- Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at B. Riley.MarketBeat
CGTX
Earnings
- 5/7/25 - Miss
CGTX
Sec Filings
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- 9/23/25 - Form SCHEDULE
- CGTX's page on the SEC website